Femasys Inc. SEC filings document the company’s women’s health medical-device business, Nasdaq-listed common stock, operating results, and product-related corporate updates. Recent 8-K filings furnish quarterly and annual financial results and disclose material events tied to executive appointments, employment agreements, financing instruments, and listing compliance matters.
Proxy materials cover annual and special stockholder meetings, board elections and governance matters, reverse stock split authorization, and share-issuance approvals linked to capital-structure provisions. Other filings describe senior secured convertible notes, warrant amendments, Nasdaq minimum bid price compliance, and the company’s emerging growth company reporting status.
FEMASYS INC director Edward R. Uzialko received a grant of 880 stock options on 2026-06-24. Each option has an exercise price of $3.67 and is exercisable for one share of common stock, covering a total of 8,800 underlying shares. The options were granted at no purchase cost and will vest one year from the grant date, assuming continued service, and are scheduled to expire on 2036-06-24. Following this grant, Uzialko holds 880 derivative securities of this type directly.
Femasys Inc. director Alistair Milnes received a new stock option award. On 2026-06-24, he was granted options to acquire 880 shares of Femasys common stock at an exercise price of $3.67 per share, expiring on 2036-06-24. The underlying shares vest one year from the grant date, assuming continued service, and this grant brings his directly held stock options from this award to 880 options.
FEMASYS INC reported that director Charles Larsen received a grant of stock options. The award covers 880 Stock Options (Right to Buy) with an exercise price of $3.67 per share, expiring on June 24, 2036. These options relate to 880 shares of Common Stock and were acquired at a price of $0.00 per option as compensation. According to the company’s disclosure, the shares underlying the option vest one year from the date of grant, assuming continued service. Following this grant, Larsen holds 880 derivative securities of this type directly.
Femasys Inc. executive Jeffrey Gerald Mifek, Chief Clinical-Medical Affairs, acquired equity-linked interests on August 7, 2026. He purchased 3,125 shares of common stock at $3.20 per share for an aggregate $10,000, and received two warrants for 3,125 shares each with a $2.95 exercise price, one immediately exercisable (subject to Nasdaq-related limitations) and one tied to future revenue and stock-price milestones.
FEMASYS INC reported that executive Jeffrey Gerald Mifek, Chief Clinical-Medical Affairs, received a grant of stock options covering 6,250 shares of common stock. The options have an exercise price of $4.08 per share and expire on July 6, 2036. The underlying shares vest in equal installments over four years beginning on July 6, 2027, contingent on continued employment. Following this grant, Mifek holds options for 6,250 shares from this award.
FEMASYS INC reported that officer Jeffrey Gerald Mifek, Chief Clinical-Medical Affairs, filed an initial ownership statement as a reporting person. He reports direct ownership of 1,411 shares of Common Stock. The filing also references an Exhibit 24 Power of Attorney authorizing representation in SEC matters.
Femasys Inc Chief Technology Officer Jeremy Alexander Sipos reported multiple transactions involving the company’s equity. He purchased 3,125 shares of common stock at $3.20 per share, for an aggregate $10,000, under a Securities Purchase Agreement dated August 7, 2026. On the same date, he was granted a warrant for 3,125 shares of common stock at an exercise price of $2.95 per share, exercisable from August 10, 2026 until August 10, 2029, subject to Nasdaq Capital Market limitations. He also received a milestone warrant for 3,125 shares at $2.95 per share, exercisable only after a future Milestone Date tied to the company achieving $1,500,000 in U.S. revenue in any fiscal quarter and certain stock price conditions; the milestone warrant’s expiration is contingent and not yet determinable.
Femasys Inc. Chief Operating Officer John Charles Canning reported acquiring both common stock and warrants. He purchased 4,375 shares of common stock at $3.20 per share under a Securities Purchase Agreement, resulting in direct ownership of 4,375 common shares. He also received two grants of 4,375 common stock purchase warrants each, with an exercise price of $2.95 per share. One warrant series is exercisable from August 10, 2026 until August 10, 2029, while the milestone warrant becomes exercisable only after a future Milestone Date tied to achieving $1,500,000 in U.S. revenue for any fiscal quarter and meeting specified volume-weighted average price conditions, and is subject to exercise limitations under Nasdaq Capital Market rules.
Femasys Inc. Chief Financial Officer Dov Elefant reported new equity transactions. On August 7, 2026, he purchased 15,625 shares of common stock at $3.20 per share for an aggregate $50,000 under a Securities Purchase Agreement. He also received two direct grants of common stock purchase warrants, each for 15,625 shares at an exercise price of $2.95 per share. One warrant is exercisable from August 10, 2026 until August 10, 2029, subject to Nasdaq Capital Market limitations. The milestone warrant becomes exercisable only after a future Milestone Date tied to achieving $1,500,000 in U.S. quarterly revenue and specified volume-weighted average price conditions.
Femasys Inc. CEO Kathy Lee-Sepsick reported acquiring company securities on August 7, 2026. She purchased 15,625 shares of Common Stock at $3.20 per share, for an aggregate $50,000, under a Securities Purchase Agreement with Femasys and other purchasers. She also received a warrant for 15,625 shares exercisable at $2.95 per share from August 10, 2026 until August 10, 2029, and a separate Milestone warrant for 15,625 shares at the same exercise price, which becomes exercisable only after specified revenue and stock-price conditions are met and is subject to Nasdaq-related exercise limitations.